ArticleBMC infectious diseases2026
Evaluation of the diagnostic performance of iChroma serological test in high SARS-CoV-2 seroprevalence setting in Gabon.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (COVID-19) has been a major global health concern over the past few years. The African region has remained less affected in terms of mortality, however, estimating the true cumulative incidence in this region is challenging due to several limitations. Serological tests can help evaluate the SARS-CoV-2 exposure at both individual and population levels. Several serological rapid tests have been developed, but their performance at population level is not always known. This current study aimed to evaluate the diagnostic performance of the iChroma test for the rapid detection of SARS-CoV-2 antibodies. Participants included in this study were recruited during the national seroprevalence household survey. The WANTAI SARS-CoV-2 Ab Enzyme-Linked Immunosorbent Assay (ELISA), was used as reference test. All samples were evaluated using both WANTAI ELISA and iChroma. In addition, a well-characterised SARS-CoV-2 rapid test (SARS-CoV-2 rapid antibody test 2.0, Roche) was evaluated on a reduced number of sample as control for rapid test using Cobas instrument. A total of 1128 samples were analysed in this study. Of the study participants, 51,2% were women with a mean age of 36 (SD: 16). Overall, 91,6% of participants had a positive WANTAI SARS-CoV-2 Ab ELISA results. In this high-seroprevalence setting, the iChroma test showed a poor agreement with the ELISA test, with a kappa value of 28 (19–38). This rapid test demonstrated a good sensitivity but a poor specificity in this setting. In contrast, we found an excellent agreement between the Roche SARS-CoV-2 rapid antibody test 2.0. and WANTAI SARS-CoV-2 Ab ELISA with a kappa value of 92% (86–98%). In this high seroprevalence setting, the specificity of iChroma test was significantly reduced and showed poorly correlation with the ELISA results. This rapid test has never been evaluated in a large scale population setting. As previously shown in other studies, Roche showed a good diagnostic performance in correlation with ELISA. The current results revealed the poor specificity of iChroma test in high SARS-CoV-2 seroprevalence settings. CLINICAL TRIAL: No applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.